ME Jan 2025 4.000 put
| Previous close | 3.3600 |
| Open | 3.3600 |
| Bid | 2.8000 |
| Ask | 3.3000 |
| Strike | 4.00 |
| Expiry date | 2025-01-17 |
| Day's range | 3.3600 - 3.3600 |
| Contract range | N/A |
| Volume | |
| Open interest | 44 |
GlobeNewswireLemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals
Lemonaid Health will offer customers more affordable access to fast-acting branded ED medication that works as quickly as 15 minutes prior to sexual activitySUNNYVALE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Lemonaid Health, Inc., a subsidiary of 23andMe Holding Co., (Nasdaq: ME), and a leading telemedicine provider, is now offering Petros Pharmaceuticals, Inc.’s (Nasdaq: PTPI), prescription erectile dysfunction (ED) medication STENDRAⓇ (avanafil) through its telehealth platform. Working direct
BloombergStruggling 23andMe Granted Extension to Revive Stock Price
(Bloomberg) -- Embattled DNA-testing firm 23andMe Holding Co. has been granted an additional 180 days to move its shares above $1 and avoid being delisted, according to a filing with the Securities and Exchange Commission.Most Read from BloombergPutin Appoints Economist as Defense Minister in Shock ReshuffleTrump Vows ‘Day One’ Executive Order Targeting Offshore WindHow One Brooklyn Neighborhood Became a Nightclub HavenTrump Pledges Across-the-Board Tax Cuts If He Returns to OfficeThe stock has
- GlobeNewswire
23andMe to Report Q4 and Full Year FY2024 Financial Results
SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the fourth quarter and full fiscal year 2024 (FY2024) after the market closes on Thursday, May 23, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discus
